Advertisement
LABU vs SSO
Which ETF would AI Choose? Direxion Daily S&P Biotech Bull 3X ETF (LABU) vs. ProShares Ultra S&P500 (SSO)
Key Takeaways
- LABU delivers 3x daily leveraged exposure to an equal-weighted biotechnology index, concentrating risk in a single high-volatility sector, while SSO provides 2x daily exposure to the broad S&P 500 Index across large-cap equities.
- LABU tracks the S&P Biotechnology Select Industry Index with approximately 150–170 holdings and an expense ratio of 0.96%, emphasizing thematic biotech exposure through swaps and futures.
- SSO tracks the S&P 500 Index with over 500 holdings and a lower expense ratio of 0.84%, offering diversified large-cap market exposure via derivatives and collateral instruments.
- Both ETFs employ daily reset leverage, making them suited for short-term tactical use rather than long-term buy-and-hold strategies due to compounding effects.
- LABU offers concentrated sector momentum potential in biotechnology but carries elevated volatility tied to clinical trials, regulatory approvals, and healthcare policy shifts.
- SSO provides broader market participation with lower relative cost and greater diversification, positioning it for general equity market trends across multiple sectors.
Introduction
Investors seeking leveraged equity exposure often compare specialized sector products with broad-market alternatives. LABU and SSO do not compete directly; instead, they represent distinct strategies. LABU targets biotechnology innovation and clinical advancement within healthcare, while SSO amplifies overall U.S. large-cap equity performance. This comparison highlights structural differences that help investors align leverage, sector focus, and risk tolerance with specific portfolio objectives in the current market environment.
Direxion Daily S&P Biotech Bull 3X ETF (LABU) Overview
The Direxion Daily S&P Biotech Bull 3X ETF (LABU) seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index. This modified equal-weighted index measures U.S. biotechnology companies classified under Global Industry Classification Standards (GICS). The fund typically holds 150–170 positions, with top holdings including companies such as Moderna, Natera, Twist Bioscience, AbbVie, and United Therapeutics. Sector allocation is nearly 100% biotechnology. It uses a passive leveraged strategy with swaps, futures, and collateral, carrying an expense ratio of 0.96%. Daily rebalancing maintains the 3x target, distinguishing it as a high-risk thematic product rather than a core holding.
ProShares Ultra S&P500 (SSO) Overview
The ProShares Ultra S&P500 (SSO) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the S&P 500 Index. The index comprises 500 leading U.S. large- and mid-cap companies selected by market capitalization. The fund maintains over 500 holdings, with significant exposure to technology leaders such as NVIDIA, Apple, Microsoft, Amazon, and Alphabet. Sector allocations span technology, financials, healthcare, consumer discretionary, and others in proportions mirroring the broad index. It employs a passive leveraged approach using swaps, futures, and money market collateral, with an expense ratio of 0.84%. Daily rebalancing sustains the 2x target, positioning it as an efficient tool for broad equity leverage.
Industry and Thematic Backdrop
Biotechnology continues to attract capital due to advances in gene editing, oncology therapies, and personalized medicine, though it faces regulatory scrutiny and clinical trial uncertainties. The broader equity market benefits from resilient corporate earnings, technological adoption in artificial intelligence, and stable economic indicators. Interest rate expectations influence both sectors, with lower rates potentially supporting growth-oriented biotech valuations and overall market multiples. Capital flows into healthcare innovation remain robust, while large-cap equities draw consistent institutional participation amid sector rotation dynamics.
Performance and Positioning Comparison
In recent market cycles, LABU has exhibited amplified moves tied to biotechnology-specific catalysts such as drug approvals and merger activity, resulting in higher volatility compared with broad-market leveraged products. SSO has tracked amplified S&P 500 movements driven by earnings growth in technology and financial sectors, offering more consistent relative positioning during equity rallies. The 3x leverage in LABU magnifies both gains and losses within its narrow sector focus, whereas the 2x structure in SSO provides moderated amplification across diversified holdings, leading to differing drawdown profiles during sector rotations or macroeconomic shifts.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.
Tickeron AI Verdict
Based on observable structural factors, Tickeron’s AI would currently assign a higher probability of favor to SSO. Its lower expense ratio, broader diversification across the S&P 500, and established liquidity profile provide greater resilience and cost efficiency relative to the concentrated, higher-cost biotechnology focus of LABU. While LABU offers targeted thematic upside in innovation-driven healthcare, the diversified risk exposure and trend consistency of SSO align more favorably with probabilistic assessments of long-term structural strength.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LABU is a Hold and SSO is a Buy.
Momentum Indicator for LABU turns positive, indicating new upward trend
LABU saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 88 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LABU just turned positive on October 21, 2026. Looking at past instances where LABU's MACD turned positive, the stock continued to rise in 49 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Following a +13.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABU advanced for three days, in 293 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
LABU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
LABU moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LABU entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Momentum Indicator for SSO turns positive, indicating new upward trend
SSO saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In 68 of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 51 cases where SSO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
SSO moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where SSO advanced for three days, in 317 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 354 of 387 cases where SSO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SSO turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 46 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
The 10-day moving average for SSO crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SSO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
| LABU | SSO | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Declines ODDS (%) | 7 days ago 90% | 7 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Advertisement